Two next‑generation incretin‑receptor agonists that have driven much of the recent metabolic‑research conversation. They share a family resemblance, but their receptor profiles and reported trial outcomes are meaningfully different.
Tirzepatide engages the GIP and GLP‑1 receptors. The dual action enhances glucose‑dependent insulin secretion and slows gastric emptying. In published Phase 3 trials (SURPASS, SURMOUNT), it produced substantial reductions in HbA1c and body weight relative to comparator GLP‑1 monoagonists.
Retatrutide adds glucagon‑receptor agonism to the GIP/GLP‑1 dual mechanism. Glucagon‑receptor activity contributes to increased energy expenditure and hepatic lipid mobilization in preclinical models. In a published Phase 2 trial (Jastreboff et al., NEJM 2023), retatrutide produced placebo‑adjusted body‑weight reductions exceeding those reported in comparable‑duration tirzepatide trials.
| Endpoint | Tirzepatide | Retatrutide |
|---|---|---|
| Weight reduction (peak doses, ~48–72 wk) | ~21–22% (SURMOUNT‑1) | ~24% at 48 wk (Phase 2) |
| HbA1c reduction (T2D populations) | ~2.0–2.5% | ~2.0% (Phase 2 in T2D) |
| GI adverse events | Nausea, diarrhea, dose‑titration sensitive | Similar profile; nausea common at higher doses |
| Heart‑rate change | Modest increase | Modest increase, possibly slightly larger |
Numbers above are summarized from publicly available peer‑reviewed publications. They are reported as observed in research populations under controlled trial conditions and are not predictions for any individual.
Both molecules are long‑chain peptides with fatty‑acid side chains designed to bind albumin and extend plasma half‑life, enabling weekly dosing in trials. Retatrutide's additional glucagon‑receptor activity is the key pharmacological distinction — it is not simply "tirzepatide plus."
Both compounds are supplied as lyophilized powders. See the Storage & Handling Guide for temperature, reconstitution, and stability guidance.
Every lot we ship includes a third‑party Certificate of Analysis verifying purity and identity. Read more on our Quality Standards page or learn how to interpret a COA in our COA Reading Guide.
All compounds discussed are intended strictly for in vitro laboratory research purposes. Nothing on this page is medical advice or an endorsement of any specific protocol. These products are not intended for human consumption, veterinary use, clinical use, or any use outside of controlled research settings, and have not been evaluated by the Food and Drug Administration.